Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies.

British journal of haematology·2026
Same author

GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.

Diabetes, obesity & metabolism·2026
Same author

Proteostasis is disrupted in human endothelial cells by serum from ATTR patients and is rescued by tafamidis treatment.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2026
Same author

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Blood advances·2026
Same author

Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma.

Blood cancer journal·2026
Same author

Unveiling the unseen: navigating heart involvement in amyloidosis with biomarkers beyond the horizons of imaging.

European heart journal. Imaging methods and practice·2026

相关实验视频

Updated: Jan 9, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.9K

轻链 (AL) 氨基粉症的新验证分期系统与IIIC阶段定义超低风险:AL国际分期系统

Jahanzaib Khwaja1,2, Amy A Kirkwood3, Paolo Milani4,5

  • 1National Amyloidosis Centre, Royal Free London, UCL, London, United Kingdom.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
|December 7, 2025
PubMed
概括

系统性轻链 (AL) 氨基粉症的新分期系统,结合纵向菌株 (LS) 和心脏生物标志物,在现代治疗时代准确地识别出具有超差预后 (IIIC 阶段) 的患者.

更多相关视频

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K
Field-Deployable Lens-Free Imaging Platform for Rapid Label-Free Analysis of Natural Killer Cell Activation
08:34

Field-Deployable Lens-Free Imaging Platform for Rapid Label-Free Analysis of Natural Killer Cell Activation

Published on: August 8, 2025

1.7K

相关实验视频

Last Updated: Jan 9, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.9K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K
Field-Deployable Lens-Free Imaging Platform for Rapid Label-Free Analysis of Natural Killer Cell Activation
08:34

Field-Deployable Lens-Free Imaging Platform for Rapid Label-Free Analysis of Natural Killer Cell Activation

Published on: August 8, 2025

1.7K

科学领域:

  • 心脏病学 心脏病学
  • 血液学 血液学 血液学
  • 医学诊断 医学诊断 医学诊断

背景情况:

  • 随着当代疗法,全身轻链 (AL) 氨基粉症的结果得到了改善.
  • 现有的风险分层模型在当前的治疗环境中可能具有有限的效用.

研究的目的:

  • 为了验证AL粉样性粉症的新型分期系统.
  • 将纵向应变 (LS) 纳入基于生物标志物的分期.
  • 评估系统在当代治疗时代 (2015-2024) 的表现.

主要方法:

  • 国际AL分期系统 (AL-ISS) 来自英国队列 (2015-2019).
  • 验证使用来自欧洲和美国 (2015-2024) 的国际患者队列进行.
  • 分析了纵向应变 (LS) 和心脏生物标志物 (NT-proBNP,Troponin-T).

主要成果:

  • AL-ISS包括LS ≥ -9%和特定的心脏生物标志物值.
  • 该系统将患者分为I,II,IIIA,IIIB和IIIC阶段.
  • 阶段IIIC独立预测了最差的结果,平均存活时间为7个月.
  • 外部验证证明了良好的预测性能 (哈雷尔C 0.69).

结论:

  • 已经建立了一个新的,经过验证的AL氨基粉症分期系统.
  • 该系统有效地识别了超贫困风险群体 (IIIC阶段).
  • 这个工具有助于在接受当代治疗的患者的预后.